BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol 2021;17:755-7. [PMID: 33508960 DOI: 10.2217/fon-2020-0986] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Rizzo A. Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al. Transl Oncol 2021;14:101246. [PMID: 34656968 DOI: 10.1016/j.tranon.2021.101246] [Reference Citation Analysis]
2 Liu G, Zhou W, Li X, Guo L, He T, Zhao J, Gong L. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. Front Immunol 2021;12:712351. [PMID: 34504494 DOI: 10.3389/fimmu.2021.712351] [Reference Citation Analysis]
3 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
4 Masterson WM, Brown AM, Al Ameri MA, Patel AB. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. Cancer Treat Res Commun 2022;30:100506. [PMID: 34990901 DOI: 10.1016/j.ctarc.2021.100506] [Reference Citation Analysis]
5 Qu C, Ma T, Yan X, Li X, Li Y; Lanzhou University Second Hospital, Lanzhou 730030, China, Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030, China. . MBE 2022;19:3069-90. [DOI: 10.3934/mbe.2022142] [Reference Citation Analysis]
6 Dai Y, Jiang H, Jiang H, Zhao S, Zeng X, Sun R, Zheng R. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis. Transl Oncol 2021;14:101238. [PMID: 34628285 DOI: 10.1016/j.tranon.2021.101238] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Li J, Xu J, Li Z. Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Transl Oncol 2021;14:101116. [PMID: 33975180 DOI: 10.1016/j.tranon.2021.101116] [Reference Citation Analysis]
8 Wu C, Luo Y, Chen Y, Qu H, Zheng L, Yao J. Development of a prognostic gene signature for hepatocellular carcinoma. Cancer Treat Res Commun 2022;31:100511. [PMID: 35030478 DOI: 10.1016/j.ctarc.2022.100511] [Reference Citation Analysis]
9 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
10 Shen YC, Lee PC, Kuo YL, Wu WK, Chen CC, Lei CH, Yeh CP, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Wu MS, Huang YH, Cheng AL. An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:809-22. [PMID: 34336726 DOI: 10.2147/JHC.S315696] [Reference Citation Analysis]
11 He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol 2021;11:716844. [PMID: 34552872 DOI: 10.3389/fonc.2021.716844] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gupta S, Khan S, Kawka M, Gujjuri R, Chau I, Starling N, Cunningham D, Jiao LR, Gall T. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34402366 DOI: 10.1080/17474124.2021.1967144] [Reference Citation Analysis]
13 Wang R, Lin N, Mao B, Wu Q. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. J Cancer Res Clin Oncol 2021. [PMID: 34297207 DOI: 10.1007/s00432-021-03716-1] [Reference Citation Analysis]
14 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Reference Citation Analysis]
15 Wang Z, Zhang S. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network. Biosci Rep 2021;41:BSR20211241. [PMID: 34212175 DOI: 10.1042/BSR20211241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50. [PMID: 33645367 DOI: 10.1080/13543784.2021.1897102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
17 Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 2021;:1-7. [PMID: 34793275 DOI: 10.1080/13543784.2022.2008354] [Reference Citation Analysis]
18 Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1077-88. [PMID: 34522690 DOI: 10.2147/JHC.S270533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cheng S, Yu X, Liu S, Jin Z, Xue H, Wang Z, Xie P. Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads. Cancer Manag Res 2021;13:9367-77. [PMID: 34992462 DOI: 10.2147/CMAR.S341672] [Reference Citation Analysis]
21 Chen Z, Ma Y, Guo Z, Song D, Chen Z, Sun M. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100669] [Reference Citation Analysis]
22 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Rizzo A, Ricci AD, Lanotte L, Lombardi L, Di Federico A, Brandi G, Gadaleta-Caldarola G. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs 2021;:1-9. [PMID: 34802383 DOI: 10.1080/13543784.2022.2009456] [Reference Citation Analysis]
24 Xing R, Gao J, Cui Q, Wang Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol 2021;12:783236. [PMID: 34899747 DOI: 10.3389/fimmu.2021.783236] [Reference Citation Analysis]
25 Wu ZH, Yang DL, Wang L, Liu J. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2021;12:793343. [PMID: 34925377 DOI: 10.3389/fimmu.2021.793343] [Reference Citation Analysis]
26 Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 2021;13:637-44. [PMID: 33820447 DOI: 10.2217/imt-2021-0026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
27 Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Rizzo A. Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option? Expert Opin Investig Drugs 2021;:1-3. [PMID: 34176423 DOI: 10.1080/13543784.2021.1948533] [Reference Citation Analysis]